AV
AVIR.US Atea Pharmaceuticals Inc
- Market cap
- USD 345M
- P/E
- -
- P/B
- 1.93x
- ROE
- -83.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AVIR.US undervalued?
Graham numberThe Graham number of Atea Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Atea Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Atea Pharmaceuticals Inc yet.
Atea Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of c…
Full company profileAtea Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Atea Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 48.6M | 351M | 192M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -17.0K | -17.0K | 10.6M | 351M | -260K | -70.1M | -83.4M | -416K | - |
| Operating Income | -9.48M | -14.6M | -11.0M | 138M | -131M | -164M | -193M | -181M | -156M |
| EBITDA | -9.46M | -14.6M | -11.0M | 138M | -130M | -120M | -132M | -164M | -147M |
| Net Income | -9.06M | -13.5M | -10.9M | 121M | -116M | -136M | -168M | -158M | -147M |
| EPS | -0.90 | -0.16 | -0.13 | 1.37 | -1.39 | -1.63 | -2.00 | -1.94 | -1.84 |
| Balance Sheet | |||||||||
| Total Assets | 34.9M | 22.1M | 864M | 773M | 667M | 595M | 465M | 315M | 201M |
| Total Liabilities | 71.0M | 71.6M | 316M | 62.8M | 26.1M | 39.8M | 25.8M | 39.8M | 25.0M |
| Shareholders' Equity | -36.2M | -49.6M | 548M | 710M | 641M | 555M | 439M | 275M | 176M |
| Cash & Short-term Investments | 34.5M | 21.7M | 850M | 764M | 647M | 578M | 455M | 302M | 191M |
| Total Debt | - | - | - | 197K | 3.12M | 2.40M | 1.64M | 843K | 213K |
| Cash Flow | |||||||||
| Operating Cash Flow | -7.91M | -12.8M | 297M | -87.0M | -121M | -85.4M | -135M | -132M | -150M |
| Capital Expenditure | 12.0K | 2.00K | 26.0K | 4.00K | 1.94M | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -7.92M | -12.8M | 297M | -87.0M | -123M | -85.4M | -135M | -132M | -150M |
| Ratios | |||||||||
| ROE | - | - | -2.0% | 17.1% | -18.1% | -24.5% | -38.4% | -57.5% | -83.9% |
| ROA | -26.0% | -61.0% | -1.3% | 15.7% | -17.4% | -22.9% | -36.2% | -50.2% | -73.4% |
| Net Profit Margin | - | - | -22.5% | 34.5% | -60.3% | - | - | - | - |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Atea Pharmaceuticals Inc dividends
Atea Pharmaceuticals Inc has not paid dividends in the last 8 fiscal years.
Who owns Atea Pharmaceuticals Inc
- Insiders 13.35%
- Institutions 79.07%
- Public & others 7.58%
- Shares outstanding 80.3M
- Free float 60.6M
Top funds holding AVIR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.13M | 3.90% | +0.86% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.03M | 2.53% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.79M | 2.24% | 0.00% | Oct 2026 |
| Fidelity Growth Company K6 | 1.22M | 1.52% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 777K | 0.97% | +0.79% | Aug 2026 |
| Fidelity Series Growth Company | 734K | 0.92% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 669K | 0.83% | 0.00% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 624K | 0.78% | +1.67% | Sep 2026 |
| iShares Biotechnology ETF | 504K | 0.63% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 412K | 0.51% | +1.23% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 373K | 0.47% | +0.23% | Oct 2026 |
| DFA U.S. Small Cap I | 350K | 0.44% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 342K | 0.43% | -4.89% | Sep 2026 |
| Fidelity Select Biotechnology | 288K | 0.36% | 0.00% | Aug 2026 |
| Dimensional US Small Cap ETF | 264K | 0.33% | 0.00% | Oct 2026 |
| JPMorgan US Small Company L | 249K | 0.31% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 235K | 0.29% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 215K | 0.27% | 0.00% | Oct 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 179K | 0.22% | +0.03% | Oct 2026 |
| Schwab Small Cap Index | 172K | 0.21% | -0.05% | Sep 2026 |
Top institutions holding AVIR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 12.0M | 14.97% | +0.45% | Jun 2026 |
| BlackRock Inc | 8.72M | 10.87% | +3.37% | Jun 2026 |
| BML Capital Management LLC | 6.95M | 8.67% | -1.51% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 4.81M | 6.00% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.96M | 3.70% | -8.66% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.08M | 2.59% | -12.07% | Jun 2026 |
| Acadian Asset Management LLC | 2.04M | 2.54% | +28.58% | Jun 2026 |
| Geode Capital Management, LLC | 1.96M | 2.44% | +12.06% | Jun 2026 |
| State Street Corp | 1.65M | 2.06% | -2.49% | Jun 2026 |
| Two Sigma Investments LLC | 1.51M | 1.88% | -19.18% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.30M | 1.62% | +0.06% | Sep 2026 |
| Renaissance Technologies Corp | 1.13M | 1.41% | -3.02% | Jun 2026 |
| Rosalind Advisors, Inc. | 1.07M | 1.33% | -8.64% | Jun 2026 |
| JPMorgan Chase & Co | 946K | 1.18% | +0.61% | Jun 2026 |
| Northern Trust Corp | 755K | 0.94% | +29.10% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 720K | 0.90% | -1.57% | Jun 2026 |
| Curated Wealth Partners LLC | 695K | 0.87% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 630K | 0.79% | +13.02% | Jun 2026 |
| Charles Schwab Investment Management Inc | 611K | 0.76% | +2.33% | Jun 2026 |
| The Goldman Sachs Group Inc | 531K | 0.66% | -9.79% | Jun 2026 |
Atea Pharmaceuticals Inc company profile
- Company name
- Atea Pharmaceuticals Inc
- Ticker
- AVIR.US
- Exchange
- USA Stocks
- Listed since
- Oct 30, 2020
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 55
- Fiscal year end
- December
- Address
- 225 Franklin Street, Boston, MA, United States, 02110
- Phone
- 857 284 8891
- Website
- ateapharma.com
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals Inc management
10- Dr. Jean-Pierre Sommadossi Ph.D.Founder, Chairman, CEO & President · born 1956
- Ms. Andrea J. Corcoran J.D.CFO, Executive VP of Legal & Secretary · born 1962
- Mr. John F. VavrickaChief Commercial Officer · born 1963
- Dr. Janet M. J. Hammond M.D., Ph.D.Chief Development Officer · born 1960
- Dr. Maria Arantxa Horga M.D.Chief Medical Officer · born 1968
- Mr. Wayne Foster CPAExecutive VP of Finance & Chief Accounting Officer · born 1969
- Ms. Jonae R. BarnesSenior Vice President of Investor Relations & Corporate Communications
- Mr. Adel Moussa Ph.D.Executive Vice President of Chemistry
- Mr. Xiao-Jian Zhou Ph.D.Executive Vice President of Early Stage Development
- Mr. Keith PietropaoloExecutive VP of Clinical Sciences & Project Management